WHO vaccine-preventable diseases: monitoring system. 2013 global summary

Last updated 20-Octl-2013 (data as of 16-Oct-2013)
Next overall update June 2014
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 18'1301 Infant (under 12 months) mortality rate: 32
GDP / capita (US$): 26'4261 Child (under 5 years) mortality rate: 42

Population data in thousands3

  2012  2011  2010  2009  2008  2000  1990  1980 
Total population 10'660  10'611  10'554  10'486  10'412  10'250  10'326  10'313 
Births 118  118  117  115  112  88  128  162 
Surviving infants 118  117  116  115  112  87  127  159 
Pop. less than 5 years 600  594  578  565  552  441  646  898 
Pop. less than 15 years 1'557  1'526  1'498  1'485  1'485  1'686  2'221  2'426 
Female 15-49 years 2'534  2'541  2'546  2'544  2'535  2'588  2'580  2'423 

Number of reported case

(Click for retrospective incidence data for Czech Republic (the))
Diphtheria
Japanese encephalitis
Measles 22  17  2'420 
Mumps 3'902  2'885  1'068  357  403  120 
Pertussis 738  324  662  956  767  187  48 
Polio*
Rubella 27  14  743 
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total)
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV);"
"it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Czech Republic (the))
Vaccine year result method % card seen                                                
BCG          99  99 
DTP1         
DTP3          99  99  99  99  98 
HepB_BD         
HepB3          99  99  99  99  99 
Hib3          99  99  99  99 
JapEnc         
MCV          97 
MCV2          98  98  98  98  97  97 
PCV1         
PCV3         
Pol3          99  99  99  99  99  97 
Rota1         
Rota_last         
Rubella1          98  98  98 
TT2plus         
PAB         
VAD1         
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: July 2014

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Czech Republic (the))
BCG 98  99  98 
DTP1 99  99  99  99  99  99 
DTP3 99  99  99  99  99  98 
HepB3 99  99  99  99  99 
Hib3 99  99  99  99  99 
MCV 98  98  98  98  97  98 
PCV3
Pol3 99  99  99  99  99  98 
Rota_last

Number of districts in the country 86  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 100
From 80 to 89% 0
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
 

Immunization Schedule (2012 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG 1 month; No risk groups
DTaP 5 years; Yes
DTaPHibHepIPV 9, 13, 17 weeks; 18 months; Yes
DTaPIPV 10 years; Yes
HPV 13 years;
HepB 12 years (x3); Yes
Influenza > 65 years; Yes
MMR 15, 21 months; Yes
Pneumo_conj 4, 5, 6, 11-18 months; Yes
Pneumo_ps
TT 25 years; Yes

Immunizaton indicators

Indicator Expected answer 2012  2011  2010  2009  2008  2007  2006 

Planning and management

Multi-year plan (MYP) for immunization Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 3 years  3 years  3years  3 years  3 years  3 years  from the beginning 2007 
Nº of districts with microplans that include activities to raise immunization coverage number 86  86  86  86  86  86  14 

National Immunization Advisory Mechanism

Does the country have a standing technical advisory group on immunization? Yes/No/NR Yes  Yes  Yes         

System performance

Total number of districts in country number 86  86  86  86  86  86  14 
Nº districts with DTP3 coverage >=80% number 86    86  86  86  86  14 
% of districts with DTP3 coverage >=80% From 0 to 100% 100    100  100  100  100  100 
Nº districts with measles (MCV1) coverage >=95% number 86    79         
% of districts with MCV1 coverage >=95% From 0 to 100% 100    92       

Safety

Monitoring of Adverse Events Following Immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
Does your country have a vaccine adverse events review committee? Yes/No/NR/ND No    No         

Finance

Percentage of routine vaccines funded by Government From 0 to 100%       100  100   

Maternal and neonatal tetanus (NT) elimination

NT eliminated Yes/No Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Sources

Unless otherwise specified, data provided by Member States through WHO-UNICEF Joint Reporting Form and WHO Regional offices.
 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2012, data for 2011
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.